Literature DB >> 17381496

The metabolic syndrome and incidence of cardiovascular disease in non-diabetic subjects--a population-based study comparing three different definitions.

P M Nilsson1, G Engström, B Hedblad.   

Abstract

AIMS: Between 1998 and 2005, a number of definitions of the metabolic syndrome (MetS) have been proposed. The aim of this population-based cohort study was to compare prevalence rates and the prediction of cardiovascular disease (CVD) using different definitions of MetS.
METHODS: A total of 5047 non-diabetic subjects (66% women), from the city of Malmö, Sweden, were followed. The incidence of fatal and non-fatal CVD (cardiac events, n = 176, and stroke, n = 171) was monitored over 11 years of follow-up. MetS was defined in three different ways [by International Diabetes Federation (IDF), National Cholesterol Education Program--Adult Treatment Panel III (NCEP-ATPIII), or European Group for the study of Insulin Resistance (EGIR) criteria] based on data on waist circumference, blood pressure, serum triglycerides, High-density lipoprotein cholesterol and fasting blood glucose. The IDF definition identified 21.9% of the subjects having the MetS. Corresponding figures for the NCEP-ATPIII and EGIR definitions were 20.7 and 18.8%, respectively.
RESULTS: After taking age, gender, low-density lipoprotein cholesterol and lifestyle factors into account, the hazard ratio (HR) for CVD event according to the IDF, NCEP-ATPIII and EGIR definitions were HR 1.11 (95% CI: 0.86-1.44), 1.59 (1.25-2.03) and 1.35 (1.05-1.74), respectively. The results were largely similar for cardiac and stroke events.
CONCLUSIONS: The prevalence of Mets according to the IDF definition was higher in comparison with NCEP-ATPIII and EGIR definitions, but the IDF definition was not superior to these definitions for prediction of CVD events. This was true for both genders and questions the usefulness of the current IDF criteria of MetS in a North-European, Caucasian population. In addition, single risk factors such as smoking had an equal prediction as the metabolic syndrome.

Entities:  

Mesh:

Year:  2007        PMID: 17381496     DOI: 10.1111/j.1464-5491.2007.02142.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  48 in total

Review 1.  Cardiovascular risk in the metabolic syndrome: fact or fiction?

Authors:  Peter M Nilsson
Journal:  Curr Cardiol Rep       Date:  2007-11       Impact factor: 2.931

Review 2.  The metabolic syndrome.

Authors:  Marc-Andre Cornier; Dana Dabelea; Teri L Hernandez; Rachel C Lindstrom; Amy J Steig; Nicole R Stob; Rachael E Van Pelt; Hong Wang; Robert H Eckel
Journal:  Endocr Rev       Date:  2008-10-29       Impact factor: 19.871

3.  Biochemical hyperandrogenism is associated with metabolic syndrome independently of adiposity and insulin resistance in Romanian polycystic ovary syndrome patients.

Authors:  Alice Albu; Serban Radian; Simona Fica; Carmen Gabriela Barbu
Journal:  Endocrine       Date:  2014-07-15       Impact factor: 3.633

4.  Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure.

Authors:  Christopher Newton-Cheh; Martin G Larson; Ramachandran S Vasan; Daniel Levy; Kenneth D Bloch; Aarti Surti; Candace Guiducci; Sekar Kathiresan; Emelia J Benjamin; Joachim Struck; Nils G Morgenthaler; Andreas Bergmann; Stefan Blankenberg; Frank Kee; Peter Nilsson; Xiaoyan Yin; Leena Peltonen; Erkki Vartiainen; Veikko Salomaa; Joel N Hirschhorn; Olle Melander; Thomas J Wang
Journal:  Nat Genet       Date:  2009-02-15       Impact factor: 38.330

5.  The relation of metabolic syndrome according to five definitions to cardiovascular risk factors--a population-based study.

Authors:  Cheng-Chieh Lin; Chiu-Shong Liu; Chia-Ing Li; Wen-Yuan Lin; Ming-May Lai; Tsann Lin; Pei-Chia Chang; Yih-Dar Lee; Ching-Chu Chen; Chih-Hsueh Lin; Chuan-Wei Yang; Chih-Yi Hsiao; Walter Chen; Tsai-Chung Li
Journal:  BMC Public Health       Date:  2009-12-23       Impact factor: 3.295

6.  Triglycerides and cardiovascular risk.

Authors:  K E L Harchaoui; M E Visser; J J P Kastelein; E S Stroes; G M Dallinga-Thie
Journal:  Curr Cardiol Rev       Date:  2009-08

7.  Metabolic syndrome: an occupational perspective.

Authors:  Chitra V Nair
Journal:  Indian J Community Med       Date:  2010-01

8.  Could pre-diabetes be considered a clinical condition? opinions from an endocrinologist and a cardiologist.

Authors:  Maria Eliane C Magalhães; Breno A Cavalcanti; Saulo Cavalcanti
Journal:  Diabetol Metab Syndr       Date:  2010-01-15       Impact factor: 3.320

9.  Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study.

Authors:  Tracey E Toms; Vasileios F Panoulas; Holly John; Karen M J Douglas; George D Kitas
Journal:  Arthritis Res Ther       Date:  2009-07-16       Impact factor: 5.156

10.  Prevalence of the metabolic syndrome in Latin America and its association with sub-clinical carotid atherosclerosis: the CARMELA cross sectional study.

Authors:  Jorge Escobedo; Herman Schargrodsky; Beatriz Champagne; Honorio Silva; Carlos P Boissonnet; Raul Vinueza; Marta Torres; Rafael Hernandez; Elinor Wilson
Journal:  Cardiovasc Diabetol       Date:  2009-09-26       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.